Ocean Biomedical Inc. (OCEA)

Overview

Ocean Biomedical, Inc. is a biopharmaceutical company with a specific focus on discovering and developing therapeutic products to address unmet needs in oncology, fibrosis, and infectious diseases. The company operates under the broader umbrella of Poseidon Bio, LLC, as a subsidiary and establishes its operational base in Providence, Rhode Island. Leveraging advanced scientific research and development, Ocean Biomedical aims to bring innovative therapeutic options to patients suffering from complex diseases such as non-small cell lung cancer, glioblastoma multiforme, and Idiopathic Pulmonary Fibrosis, along with combating prevalent infectious diseases like malaria.

Products and Services

Ocean Biomedical, Inc. is developing a range of product candidates, each targeting critical medical conditions through novel therapeutic approaches:

• Antibody Therapeutic Candidate Inhibiting Chi3l1: This product is designed for the treatment of non-small cell lung cancer and glioblastoma multiforme, potentially offering a new avenue for patients with these challenging diagnoses.
• Bi-specific Antibody Product Candidate Inhibiting Chi3l1 plus PD-1 and CTLA-4: By targeting multiple pathways, this therapy aims to enhance anti-tumor activity against non-small cell lung cancer and glioblastoma multiforme, representing an advanced approach in cancer treatment.
• Small Molecule Product Candidate Targeting Chit1: Aimed at treating Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome, this candidate focuses on a novel target, potentially offering a new treatment paradigm for fibrosis-related conditions.
• WPDS Platform-Based Product Candidates:
  • Malaria Vaccine Candidate: This preventive approach targets malaria, focusing on creating a safer and more effective vaccine against the disease.
  • Humanized mAb Malaria Therapeutic Candidate Targeting PfGARP: This therapeutic approach aims to treat malaria by targeting specific proteins associated with the disease, showcasing Ocean Biomedical’s commitment to infectious disease research.
  • Small Molecule Malaria Therapeutic Candidate Targeting PfGARP: Similar to the humanized mAb candidate, this product aims to offer a different modality in attacking the malaria parasite, potentially improving treatment outcomes for patients.